EMAL1 Antibody (N-term) Blocking Peptide
€363.00
In stock
SKU
AC-BP6733a
Background:
Human echinoderm microtubule-associated protein-like is a strong candidate for the Usher syndrome type 1A gene. Usher syndromes (USHs) are a group of genetic disorders consisting of congenital deafness, retinitis pigmentosa, and vestibular dysfunction of variable onset and severity depending on the genetic type. The disease process in USHs involves the entire brain and is not limited to the posterior fossa or auditory and visual systems. The USHs are catagorized as type I (USH1A, USH1B, USH1C, USH1D, USH1E and USH1F), type II (USH2A and USH2B) and type III (USH3). The type I is the most severe form.
Other Names:
Echinoderm microtubule-associated protein-like 1, EMAP-1, HuEMAP-1, EML1, EMAP1, EMAPL, EMAPL1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6733a was selected from the N-term region of human EMAL1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: EML1
Gene ID: 2009
Primary Accession: O00423
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Human echinoderm microtubule-associated protein-like is a strong candidate for the Usher syndrome type 1A gene. Usher syndromes (USHs) are a group of genetic disorders consisting of congenital deafness, retinitis pigmentosa, and vestibular dysfunction of variable onset and severity depending on the genetic type. The disease process in USHs involves the entire brain and is not limited to the posterior fossa or auditory and visual systems. The USHs are catagorized as type I (USH1A, USH1B, USH1C, USH1D, USH1E and USH1F), type II (USH2A and USH2B) and type III (USH3). The type I is the most severe form.
Other Names:
Echinoderm microtubule-associated protein-like 1, EMAP-1, HuEMAP-1, EML1, EMAP1, EMAPL, EMAPL1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6733a was selected from the N-term region of human EMAL1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: EML1
Gene ID: 2009
Primary Accession: O00423
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review